Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials

Content Provider	Scilit
Author	Wei, Jinli Luo, Yulin Fu, Deyuan
Copyright Year	2018
Description	Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials Jinli Wei,* Yulin Luo,* Deyuan Fu Department of Thyroid and Breast Surgery, Northern Jiangsu People's Hospital, Yangzhou 225001, Jiangsu, People's Republic of China *These authors contributed equally to this work Purpose: To better clarify the efficacy of neoadjuvant bevacizumab plus chemotherapy (BEV + CT) vs chemotherapy (CT) alone in the treatment of HER2-negative nonmetastatic breast cancer. Methods: PubMed, Embase, Web of Science, and Cochrane Library databases were searched for relevant articles published from January 1, 2000 to July 31, 2018. Review Manager software version 5.3 was used to perform this meta-analysis. Results: Six randomized controlled trials matched the selection criteria, yielding a total of 4,354 patients with early outcomes and 3,777 patients with late outcomes. Pooled pathological complete response (pCR) and 5-year disease-free survival (DFS) rates were higher for the neoadjuvant BEV + CT group (OR =1.37 [1.19, 1.58]; P<0.001 and HR =0.84 [0.72, 0.98]; P=0.020, respectively), but 5-year overall survival (OS) rate showed no significant difference (HR =0.79 [0.55, 1.11]; P=0.180). Subgroup analysis showed that the pCR rate was significantly higher in both patients with hormone receptor (HR)-positive breast cancer (OR =1.30 [1.01, 1.66]; P=0.040) and those with HR-negative breast cancer (OR =1.52 [1.25, 1.83]; P<0.001) in BEV + CT group. Conclusion: Compared with CT alone, neoadjuvant BEV + CT significantly improved the 5-year DFS rate of HER2-negative breast cancer patients, but showed no benefit in terms of 5-year OS rate. Keywords: bevacizumab, neoadjuvant chemotherapy, breast cancer, HER2-negative, randomized controlled trial
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296181/pdf https://www.dovepress.com/getfile.php?fileID=46893
Ending Page	9059
Page Count	11
Starting Page	9049
ISSN	11786930
DOI	10.2147/ott.s186816
Journal	OncoTargets and therapy
Volume Number	11
Language	English
Publisher	Informa UK Limited
Publisher Date	2018-12-01
Access Restriction	Open
Subject Keyword	Oncology Bevacizumab Neoadjuvant Chemotherapy Breast Cancer Her2-negative Randomized Controlled Trial
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Oncology